NO981858L - Fenyletanolamin-forbindelser anvendelige som <beta>3 agonist, fremgangsmÕte for fremstilling av disse og mellomprodukter i fremstilling av dem - Google Patents

Fenyletanolamin-forbindelser anvendelige som <beta>3 agonist, fremgangsmÕte for fremstilling av disse og mellomprodukter i fremstilling av dem

Info

Publication number
NO981858L
NO981858L NO981858A NO981858A NO981858L NO 981858 L NO981858 L NO 981858L NO 981858 A NO981858 A NO 981858A NO 981858 A NO981858 A NO 981858A NO 981858 L NO981858 L NO 981858L
Authority
NO
Norway
Prior art keywords
lower alkoxy
preparation
substituted
intermediates
represents hydrogen
Prior art date
Application number
NO981858A
Other languages
English (en)
Norwegian (no)
Other versions
NO981858D0 (no
Inventor
Susumu Tsuchiya
Nobuyuki Yasuda
Toshifumi Matsumoto
Kozo Hiratsuka
Hiroyuki Iizuka
Atsusi Hukuzaki
Kouichi Matsunaga
Original Assignee
Tokyo Tanabe Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokyo Tanabe Co filed Critical Tokyo Tanabe Co
Publication of NO981858D0 publication Critical patent/NO981858D0/no
Publication of NO981858L publication Critical patent/NO981858L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/24Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/36Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08Radicals containing only hydrogen and carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO981858A 1995-10-26 1998-04-24 Fenyletanolamin-forbindelser anvendelige som <beta>3 agonist, fremgangsmÕte for fremstilling av disse og mellomprodukter i fremstilling av dem NO981858L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP27855495 1995-10-26
JP24962296 1996-09-20
PCT/JP1996/003097 WO1997015549A1 (fr) 1995-10-26 1996-10-24 COMPOSES DE PHENYLETHANOLAMINE UTILES EN TANT QUE β3 AGONISTES, LEURS PROCEDE ET INTERMEDIAIRES DE PRODUCTION

Publications (2)

Publication Number Publication Date
NO981858D0 NO981858D0 (no) 1998-04-24
NO981858L true NO981858L (no) 1998-06-24

Family

ID=26539396

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981858A NO981858L (no) 1995-10-26 1998-04-24 Fenyletanolamin-forbindelser anvendelige som <beta>3 agonist, fremgangsmÕte for fremstilling av disse og mellomprodukter i fremstilling av dem

Country Status (12)

Country Link
US (1) US6069176A (ko)
EP (1) EP0940387B1 (ko)
JP (1) JP3926390B2 (ko)
KR (1) KR100483635B1 (ko)
AT (1) ATE239694T1 (ko)
AU (1) AU715216B2 (ko)
CZ (1) CZ126598A3 (ko)
DE (1) DE69628051T2 (ko)
ES (1) ES2193266T3 (ko)
HU (1) HUP9802318A3 (ko)
NO (1) NO981858L (ko)
WO (1) WO1997015549A1 (ko)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4685201B2 (ja) * 1996-08-19 2011-05-18 キッセイ薬品工業株式会社 頻尿および尿失禁の予防・治療剤
WO1998024754A1 (fr) * 1996-12-04 1998-06-11 Kureha Kagaku Kogyo Kabushiki Kaisha Derives de la cyclopentyleamine, leur procede de preparation et bactericides
ATE423555T1 (de) * 1998-04-06 2009-03-15 Astellas Pharma Inc Verwendung von beta-3-adrenergen-rezeptoren agonisten in der behandlung von dysurie
US6184236B1 (en) 1998-08-18 2001-02-06 Hoffmann-La Roche Inc. Method of treating a neurodegenerative disease by administering an aryl-cyclohexylamine derivative
EP0982026B1 (en) * 1998-08-18 2006-05-17 F. Hoffmann-La Roche Ag Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers
US6828460B2 (en) 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
CA2398199A1 (en) * 2000-01-28 2001-08-02 Asahi Kasei Kabushiki Kaisha Novel therapeutic agents that use a .beta.3 agonist
JP2003531187A (ja) 2000-04-26 2003-10-21 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー サブタイプ選択的nmda受容体アンタゴニストとしてのシクロヘキシルアミン誘導体
WO2001092204A1 (en) * 2000-06-01 2001-12-06 Warner-Lambert Company Cyclohexylamine derivatives as subtype selective nmda receptor antagonists
ES2243500T3 (es) * 2000-06-06 2005-12-01 Warner-Lambert Company Llc Ciclohexilaminas biciclicas y uso como antegonistas del receptor nmda.
US6514991B2 (en) * 2000-07-17 2003-02-04 Wyeth Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists
US6410734B1 (en) * 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
US6395762B1 (en) 2000-07-17 2002-05-28 American Home Products Corporation Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6458817B1 (en) 2000-07-17 2002-10-01 Wyeth Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists
US6509358B2 (en) 2000-07-17 2003-01-21 Wyeth Piperidino-phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6498170B2 (en) 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
US20040018959A1 (en) * 2002-05-02 2004-01-29 Randall S. Hickle System and methods of lipid removal from the body
GB0217211D0 (en) 2002-07-24 2002-09-04 Syngenta Participations Ag Organic compounds
PT1559427E (pt) 2002-11-07 2011-05-27 Astellas Pharma Inc Medicamento para bexiga hiperactiva que cont?m um derivado da anilida do ?cido ac?tico como componente activo
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
SI1599468T1 (sl) * 2003-01-14 2008-02-29 Arena Pharm Inc 1,2,3-trisubstituirani arilni in heteroarilni derivati kot modulatorji metabolizma ter profilaksa in zdravljenje motenj v zvezi z njim, kot diabetesain hiperglikemije
BRPI0406761A (pt) 2003-01-14 2005-12-20 Arena Pharm Inc Derivados de arila e heteroarila 1,2,3-trissubstituìdos como moduladores do metabolismo e a profilaxia e tratamento de distúrbios relacionados a estes tais como diabetes e hiper-glicemia
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AU2004285289A1 (en) * 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor
US20050250944A1 (en) * 2004-05-04 2005-11-10 Jian Chen Synthesis and uses of synephrine derivatives
JP4959569B2 (ja) * 2004-10-12 2012-06-27 グレンマーク・ファーマシューティカルズ・エスエー 新規なジペプチジルペプチダーゼiv阻害剤、それらを含む医薬品組成物、およびそれらを調製するためのプロセス
US7544841B2 (en) * 2004-10-20 2009-06-09 Mitsubishi Tanabe Pharma Corporation Production method of phenylethanolamine compound, and its intermediate
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
WO2007083640A1 (ja) * 2006-01-18 2007-07-26 Kyorin Pharmaceutical Co., Ltd. 頻尿及び尿失禁の予防又は治療剤
WO2008024787A1 (en) * 2006-08-23 2008-02-28 Medicinova, Inc. Method of treatment or prophylaxis of depression
KR100821567B1 (ko) 2006-11-01 2008-04-15 한국화학연구원 광학 활성 2-설포닐옥시-1-페닐에탄올 유도체의 제조방법
US20080200467A1 (en) * 2006-11-02 2008-08-21 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
US8217027B2 (en) * 2006-12-21 2012-07-10 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
BRPI0811639A2 (pt) 2007-05-31 2014-09-30 Sepracor Inc Cicloaquilaminas fenil substituídas como inibidores da recaptação de monoamina
WO2009065406A2 (en) * 2007-11-23 2009-05-28 Leo Pharma A/S Novel cyclic hydrocarbon compounds for the treatment of diseases
JP5968880B2 (ja) * 2010-06-30 2016-08-10 レオ ファーマ アクティーゼルスカブ カルシウム模倣化合物の新規多形
EP2588444A1 (en) * 2010-06-30 2013-05-08 Leo Pharma A/S New polymorphic form of a calcimimetic compound
SG187689A1 (en) 2010-08-03 2013-03-28 Altherx Inc Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
AU2011305525B2 (en) 2010-09-22 2016-08-18 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
ES2394349B1 (es) 2012-08-29 2013-11-04 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
JP6450660B2 (ja) * 2014-08-25 2019-01-09 住友化学株式会社 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法
US9956194B2 (en) 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
IL285890B (en) 2015-06-22 2022-07-01 Arena Pharm Inc Slate-free crystal of the arginine salt of (Ar)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-4,3,2,1-tetrahydro-cyclopent[b]indole-3-yl ) acetic acid
ES2967863T3 (es) 2015-10-23 2024-05-06 B3Ar Therapeutics Inc Ion dipolar de solabegron y usos del mismo

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4940226B1 (ko) * 1970-05-02 1974-10-31
US3803232A (en) * 1970-09-30 1974-04-09 Ciba Geigy Corp Arylcarboxamidines
JPS517617B2 (ko) * 1972-08-25 1976-03-09
US4350685A (en) * 1981-02-06 1982-09-21 Smithkline Corporation Antiallergic imidodisulfamides
JPS62198639A (ja) * 1986-02-26 1987-09-02 Takasago Corp α−アリ−ルカルボニル誘導体の製造法
US4755505A (en) * 1987-08-18 1988-07-05 American Home Products Corporation 1-[2-(dialkylamino)alkyl]-4,5-dihydro-4-(aryl)-1-benzazocine-2,6(1H,3H)-diones as anti-arrhythmic agents
JPH0819032B2 (ja) * 1987-11-20 1996-02-28 三井東圧化学株式会社 2−(4−ヒドロキシフェニル)−シクロヘキサノンの製造方法
FR2643076B1 (fr) * 1989-02-14 1991-06-21 Midy Spa Carboxyalkyl-ethers de la 2-amino-7-hydroxytetraline
DE4006937A1 (de) * 1990-03-06 1991-09-12 Basf Ag 4-(4-tert.-butylphenyl)cyclohexylamine und diese enthaltende fungizide
JP2971938B2 (ja) * 1990-11-01 1999-11-08 ダイセル化学工業株式会社 分離剤
GB9107827D0 (en) * 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
JP2932330B2 (ja) * 1991-10-28 1999-08-09 雪印乳業株式会社 含窒素化合物の水素化還元方法
DE4210569A1 (de) * 1992-03-31 1993-10-07 Hoechst Ag Verwendung von substituierten µ-Hydroxyethylaminen als fungizide Wirkstoffe

Also Published As

Publication number Publication date
NO981858D0 (no) 1998-04-24
AU7335896A (en) 1997-05-15
CZ126598A3 (cs) 1998-09-16
HUP9802318A3 (en) 2001-04-28
ES2193266T3 (es) 2003-11-01
AU715216B2 (en) 2000-01-20
JP3926390B2 (ja) 2007-06-06
DE69628051T2 (de) 2004-02-26
KR100483635B1 (ko) 2005-12-21
EP0940387A4 (en) 2000-07-05
EP0940387A1 (en) 1999-09-08
WO1997015549A1 (fr) 1997-05-01
ATE239694T1 (de) 2003-05-15
EP0940387B1 (en) 2003-05-07
US6069176A (en) 2000-05-30
DE69628051D1 (de) 2003-06-12
HUP9802318A2 (hu) 1999-08-30
KR19990067089A (ko) 1999-08-16

Similar Documents

Publication Publication Date Title
NO981858L (no) Fenyletanolamin-forbindelser anvendelige som &lt;beta&gt;3 agonist, fremgangsmÕte for fremstilling av disse og mellomprodukter i fremstilling av dem
EP1416933B8 (en) Substituted piperidines as modulators of the melanocortin receptor
TW200606152A (en) Piperidine compound and process for preparing the same
NO20071660L (no) Nye pyridinonderivater og deres anvendelse som positive allosteriske modulatorer av MGLUR2-reseptorer
EA200800886A1 (ru) Способ получения 1-н-имидазо[4,5-с]пиридинов и их аналогов
NO20065578L (no) Substituerte metylaryl eller heteroarylamidforbindelser
IL189156A (en) A bite-containing (theo-hydrazide-rich) preparation, a flake cation and a thickening additive, a method for making this lipophilate and the leophilizate
PL1742957T3 (pl) Sposób otrzymywania telitromycyny
MX9701305A (es) Piperidinas sustituidas novedosas utiles para el tratamiento de enfermedades alergicas.
NO20062061L (no) Nye substituerte, 4-amino-tiazolo[4,5-D]pyriminder, nyttige som kjemokinreseptorantagonister, ESP. CX3CR1
IL154271A0 (en) Compounds acting as melanocortin receptor ligands
MX9707879A (es) Derivados de piperazina sustituidos novedosos que tienen actividad antagonista de receptor de taquinina.
NO20055143L (no) Doseringsformer innbefattende AG013736
NO20045528L (no) MHC1R-antagonister
EP1484352A4 (en) THIOEPOXY-BASED POLYMERIZABLE COMPOSITION AND PROCESS FOR PRODUCING SUCH COMPOSITION
NO20063230L (no) CRF receptorantagonister og fremgangsmater for fremstilling derav
UA95922C2 (en) Glucuronate salt of a piperazine compound
WO2004089366A8 (en) Bicyclic compounds as nr2b receptor antagonists
NO20023161L (no) Substituerte piperidiner, legemidler inneholdende disse forbindelser og fremgangsmåter for fremstilling av dem
TW200514781A (en) Novel compounds
EP1443046A4 (en) NEW 4- (2-FUROYL) -AMINO-PIPERIDINES, INTERMEDIATES FOR THEIR SYNTHESIS, METHOD FOR THE PRODUCTION THEREOF AND THEIR MEDICAL USE
MX2009010727A (es) Heterociclos como antagonistas de orexina.
WO2009007536A8 (fr) Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique
DK1673354T3 (da) Arylindenopyridiner og arylindenopyrimidiner og deres anvendelse som adenosin-A2a-receptorantagonister
MXPA03010960A (es) Proceso para la produccion de fexofenadina derivado de piperidina.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application